Please select the eligibility criteria that correspond to the clinical trial below.
Title: An RCT Evaluating the Implantation Potential of Vitrified Embryos Screened by Next Generation Sequencing Following Trophectoderm Biopsy, Versus Vitrified Unscreened Embryos in Good Prognosis Patients Undergoing IVF
Brief Summary: This is a two-arm parallel group randomized controlled trial at the Department of Reproductive Medicine at Ghent University Hospital. Women \>=18 and \<37 years of age undergoing their first or second IVF/ICSI treatment, with at least 2 good quality blastocysts remaining after fresh embryo transfer will be randomized to either transfer of a cryopreserved blastocyst selected based on morphology (standard treatment arm) or transfer of a cryopreserved blastocyst selected based on PGS and morphology (intervention treatment arm).


Options:
A: Inclusion Criteria:

* Patient undergoing IVF/CCS (no PGD banking)
* Patient meets ASRM guidelines for Double Embryo Transfer (DET)
* Donor Sperm OK
* AMH ≥ 1.2
* FSH ≤ 12
* BAFC ≥12
* Max 1 prior failed IVF cycle for patients 35-45 years old
* Patient \<35 years old MUST have 1 prior failed IVF cycle

Exclusion Criteria:

* Chronic endometrial insufficiency
* Use of oocyte donor or gestational carriers
* Medical contraindications to Double Embryo Transfer (DET)
* Male Factor (\<100,000 sperm or surgical sperm)
* Communicating hydrosalpinx (on HSG)
* Single gene disorders or sex selection
B: Inclusion Criteria:

* Patient undergoing in vitro fertilization (IVF)
* Normal uterine function by ultrasound and absence of hysteromyoma
* Regular menstrual cycle of 25-35 days
* Normal hormone levels (WHO standard) for LH, PRL, E2, PROG, TEST and TSH
* FSH 1-12 IU/L and follicle number \> 5 on day 2-3 of menstrual cycle
* Minimum of 3 blastocysts on day 5 of embryo development
* Signed consent form

Exclusion Criteria:

* Known endometriosis
* Abnormal vaginal bleeding with no known cause
* Known genital organ system malformation, unsuitable to conceive
* Known currently active pelvic inflammation
* Abnormal liver, kidney lab results, with clinical implications.
* Known endocrine or metabolic disorders (pituitary gland, adrenal glands, pancreas, liver or kidney）
* Known ovarian, breast, uterine, adrenal glands, pituitary gland or hypothalamus tumor
* Known abnormal cervical cancer lesions, with clinical implications, within one year before PGS
* History of chemo- or radio-therapy
* Seropositive for HIV, Hep B, Hep C or TPPA/RPR (Syphilis)
* Known ovarian poor response in previous cycles, i.e. after administration of GnRH for \> 20 days
* More than 2 implantation failures
* More than 2 miscarriages
* Known altered parental karyotype such as Robertsonian or reciprocal translocation
* Use of sperm or oocyte donors
* Severe male factor (surgical retrieval of sperm)
* Preimplantation genetic diagnosis cycles for single gene diseases or sex selection
* Participation in other IVF research studies
* Patient refusal or inability to follow the protocol for any good reason, including clinical visit or lab test
C: Inclusion Criteria:

* at least 2 blastocysts suitable for biopsy on day 5 of embryo development remaining after fresh transfer
* willing and able to give informed consent
* infertility as an indication for IVF/ICSI
* first or second IVF/ICSI cycle
* patients willing to accept single embryo transfer
* BMI range 18 to 35 kg/m2

Exclusion Criteria:

* any type of genetic abnormality or family history of genetic abnormality in subject or partner
* any other non-study related preimplantation genetic testing
* three or more clinical miscarriages (recurrent pregnancy loss, RPL)
* recurrent implantation failure (RIF): no positive β-hCG after transfer (fresh IVF/ICSI cycle or frozen) with no less than 6 cleavage stage embryos or no less than 4 blastocysts, all of good quality and of appropriate developmental stage
* severe endometriosis
* abnormal uterine cavity
* cycles requiring surgical sperm recovery procedures, total asthenozoospermia and/or globozoospermia
* treatment involving use of donor oocytes or use of gestational carrier
D: Inclusion Criteria:

Women 18-48 years of age who are scheduled for IVF or ICSI with a history of recurrent spontaneous abortion (continous miscarriage occurred earlier than 20 weeks of gestation for equal or greater than 2 times) in our IVF institute while meeting the following criteria:

1. regular menstrual cycles and normal level of E2, P, FSH, LH, T, RPL in the early follicular phase;
2. no history of hormone medicine application in the last 3 months;
3. no history of poison contact;
4. normal uterine and adnexal ultrasonography;
5. TORCH(-), chlamydia(-), mycoplasma(-), normal leucorrhoea routine, anti-phospholipid antibody (-), antinuclear antibody(-);
6. for the couple, no blood type incompatibility or ABO antibody IgG≤1：64 and normal blood chromosome analysis.

Exclusion Criteria:

1. hydrosalpinx without operation; endometriosis; polycystic ovary syndrome; adenomyosis; uterine leiomyomata(submucous myoma or non-submucous myoma which size was exceed 4cm and/or with the compressed endometrium);uterine cavity lesions(such as uterine malformation, intrauterine adhesions, the septate uterus, endometritis etc);
2. the former abortion is because of luteal phase defect without treatment;
3. thyroid dysfunction or increased CA125 level;
4. acute inflammation of genitourinary system or STD carriers;
5. unable to comply with the study procedures.

Answer: C